The sharpest tension today sits in biotech. NTLA (Intellia Therapeutics) is up 31% year-to-date and options traders are turning bullish. Yet short sellers are not budging — the stock carries a short score of 77 and days-to-cover of 6.8. Analysts see 104% upside from here. That gap between bearish positioning and bullish options flow is one of the most watched setups in the market right now. Nearby, PPLI jumped 11% today as a similar tug-of-war sharpened between call buyers and short sellers.
MRNA tells the clearest short-cover story of the week. SI dropped nearly 2 percentage points to 8.1% of free float after positive ESMO cancer vaccine data pushed the stock past $200. Bears caught offside are booking losses and leaving.
Micron Technology reports Q4 2026 results on Wednesday. It is the week's biggest scheduled macro read on AI hardware demand. Chipmakers and data centre investors will parse every line of guidance. adds consumer-spending colour on Thursday after the bell.
On the analyst front, Charles River Laboratories picked up two target upgrades after earnings. Darden Restaurants drew a $40 spread between bull and bear targets — reflecting real disagreement on the consumer outlook. In Europe, a MOL board director made a notable open-market purchase, sending a constructive signal even as energy markets stay choppy.
GME short interest rocketed from 0.9% to 7.5% in a week. Bears are back. Meanwhile, SPCX shorts built to 30.6% of free float on the newly listed SpaceX entity — a major bearish position on a $1.2 trillion market cap name.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
